ASML's Union Standoff and the 800 Billion Dollar Question Shareholders Must Weigh

ASML finds itself squeezed between two very different kinds of pressure. On one side, Dutch unions are weighing legal action over changes to the company's reorganisation timetable. On the other, investors are being asked to judge whether a striking long-term valuation forecast — one that puts the chip equipment maker at 800 billion US dollars by 2029 — can survive contact with reality.

A Schedule Dispute With Legal Teeth

The friction centres on the Technology Transition programme. According to the FNV union, ASML has pushed the start date back to 7 December 2026. For the IT division, the union cites 8 March 2027 as the new kick-off. ASML, for its part, says the delay touches roughly 30 employees and sees no need to reopen negotiations over the social plan.

That last point matters. The FNV walked away from talks citing both the revised dates and ASML's reading of the social plan itself, so the conflict is not merely about timing — it is also a dispute over how the agreed rules should be interpreted. Legal options are being explored, though no proceedings have yet been formally announced.

What the Market Actually Reacted To

Meanwhile, the share price told a quieter story. ASML stock slipped 0.059% on Friday, a move media reports attributed to the resignation of Nvidia chief Jensen Huang and the broader turbulence that rippled through the semiconductor sector — not to any fresh company-specific announcement from ASML. The next concrete date on the reorganisation calendar remains the December start of the Technology Transition flagged by the FNV.

The Bull Case Rests on Earnings, Not Headlines

Set against that noise, the valuation debate turns on something far more fundamental: profit. The Motley Fool's projection assumes market capitalisation compounding at 12.7% a year, a pace that would deliver the 800 billion dollar mark around mid-2029. Whether that holds depends almost entirely on whether earnings growth can carry the multiple.

The starting point is genuinely strong. ASML posted quarterly revenue of 11.7 billion euros and a net profit of 5 billion euros, with a gross margin of 57.5%. Turning one standout quarter into a durable earnings trajectory is the task that would justify a richer valuation — and the number to watch is earnings per share.

The Earnings Hurdle

Analysts have pencilled in 56.43 euros per share for 2027, a 36% increase. For 2026, the consensus sits at 41.48 euros, which would mark a rise of roughly 68% year on year. Those forecasts are what link the operating business to the valuation question: hit them, and a higher enterprise value can be defended through growing profits; miss them, and the argument weakens fast.

There is supporting evidence beyond the income statement. Non-current contract liabilities climbed from 3.6 billion to 9.3 billion euros in the reported quarter — a balance-sheet signal that gains meaning if it converts into revenue and profit on schedule. On the capacity side, ASML plans to expand EUV production by 30% in 2027 and is examining a further increase the following year that could be larger still. More output could mean higher sales, provided customers take delivery and margins hold.

Valuation Has Already Come Down

One detail reframes the risk. The price-to-earnings ratio on forward estimates sits at around 23, down from roughly 47 at the end of June. A lower multiple offers a more forgiving entry point — but only if the underlying earnings estimates hold. If they are cut, the stock's appeal has to be reassessed against the reduced expectations, and that is where the optimistic case is most exposed.

China is expected to contribute about 20% of ASML's revenue in 2026, so a softer performance there could weigh on growth assumptions. Execution on the production build-out is another variable: delays, or thinner profitability on incremental sales, could leave earnings short of forecasts. The record quarter's high margin, in other words, sets a demanding bar for comparison.

The Date That Settles the Argument

The next set of results is scheduled for 27 January 2027, and it will serve as the practical test of whether business momentum and company guidance still support the expected earnings jump. Investors would do well to read revenue, profitability and commentary on the capacity expansion together — higher sales strengthen the bull case most when they come with continued strong profits, while a softer margin outlook could justify caution even as the top line grows.

As long as the earnings path holds and the build-out stays on track, the case for a rising valuation remains coherent. Should profit expectations falter, the long-range model loses its footing too. For anyone weighing the shares, the next credible earnings picture carries more weight than any single valuation target — and rather more than a 0.059% move on a Friday.